PRAME immunohistochemistry distinguishes nodal nevi from metastatic melanoma

Abstract Background Preferentially expressed antigen in melanoma (PRAME) is a promising immunohistochemical marker for distinguishing benign from malignant melanocytic lesions in lymph node deposits. Objective To evaluate PRAME expression in metastatic melanomas and nevi found in the sentinel lymph...

Full description

Saved in:
Bibliographic Details
Main Authors: Hortência Gomes da Silveira, Hercilio Fronza Junior, Larissa D’Espirro de Souza Campos, Jaqueline Stall, Rodrigo Blasius, Camila Kricheski, Bruna Louise Silva, Paulo Henrique Condeixa de França, Karina Munhoz de Paula Alves Coelho
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Surgical and Experimental Pathology
Subjects:
Online Access:https://doi.org/10.1186/s42047-024-00171-3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846112612953096192
author Hortência Gomes da Silveira
Hercilio Fronza Junior
Larissa D’Espirro de Souza Campos
Jaqueline Stall
Rodrigo Blasius
Camila Kricheski
Bruna Louise Silva
Paulo Henrique Condeixa de França
Karina Munhoz de Paula Alves Coelho
author_facet Hortência Gomes da Silveira
Hercilio Fronza Junior
Larissa D’Espirro de Souza Campos
Jaqueline Stall
Rodrigo Blasius
Camila Kricheski
Bruna Louise Silva
Paulo Henrique Condeixa de França
Karina Munhoz de Paula Alves Coelho
author_sort Hortência Gomes da Silveira
collection DOAJ
description Abstract Background Preferentially expressed antigen in melanoma (PRAME) is a promising immunohistochemical marker for distinguishing benign from malignant melanocytic lesions in lymph node deposits. Objective To evaluate PRAME expression in metastatic melanomas and nevi found in the sentinel lymph nodes of patients with primary melanoma. Methods Thirty patients, comprising 15 nodal nevi and 15 metastatic melanomas, were immunohistochemically analyzed for PRAME expression. Nuclear expression was scored as 0–25%, > 25–50%, > 50–75% or > 75% in tumor cells. The sensitivity, specificity, and positive and negative predictive values were calculated considering nuclear expression of PRAME > 75% as positive cases. Results Cases previously diagnosed as nodal nevi were uniformly negative for PRAME. Conversely, all cases diagnosed as melanoma showed PRAME expression in more than 50% of the cells. Twelve cases showed expression above 75% of cells and were considered positive for calculations, resulting in sensitivity and specificity rates of 80% and 100%, respectively, with corresponding positive and negative predictive values of 100% and 83%. Conclusions A high level of PRAME immunoreactivity was identified in metastatic melanoma, suggesting that PRAME is a useful analytical tool for confirming the diagnosis of melanoma in a melanocytic nodal deposit.
format Article
id doaj-art-1f6e794b392a4eddb044d37a7894269e
institution Kabale University
issn 2520-8454
language English
publishDate 2024-12-01
publisher BMC
record_format Article
series Surgical and Experimental Pathology
spelling doaj-art-1f6e794b392a4eddb044d37a7894269e2024-12-22T12:24:39ZengBMCSurgical and Experimental Pathology2520-84542024-12-01711710.1186/s42047-024-00171-3PRAME immunohistochemistry distinguishes nodal nevi from metastatic melanomaHortência Gomes da Silveira0Hercilio Fronza Junior1Larissa D’Espirro de Souza Campos2Jaqueline Stall3Rodrigo Blasius4Camila Kricheski5Bruna Louise Silva6Paulo Henrique Condeixa de França7Karina Munhoz de Paula Alves Coelho8Universidade da Região de Joinville - UNIVILLECentro de Diagnósticos Anátomo-Patológicos - CEDAPCentro de Diagnósticos Anátomo-Patológicos - CEDAPUniversidade da Região de Joinville - UNIVILLECentro de Diagnósticos Anátomo-Patológicos - CEDAPCentro de Diagnósticos Anátomo-Patológicos - CEDAPUniversidade da Região de Joinville - UNIVILLEUniversidade da Região de Joinville - UNIVILLEUniversidade da Região de Joinville - UNIVILLEAbstract Background Preferentially expressed antigen in melanoma (PRAME) is a promising immunohistochemical marker for distinguishing benign from malignant melanocytic lesions in lymph node deposits. Objective To evaluate PRAME expression in metastatic melanomas and nevi found in the sentinel lymph nodes of patients with primary melanoma. Methods Thirty patients, comprising 15 nodal nevi and 15 metastatic melanomas, were immunohistochemically analyzed for PRAME expression. Nuclear expression was scored as 0–25%, > 25–50%, > 50–75% or > 75% in tumor cells. The sensitivity, specificity, and positive and negative predictive values were calculated considering nuclear expression of PRAME > 75% as positive cases. Results Cases previously diagnosed as nodal nevi were uniformly negative for PRAME. Conversely, all cases diagnosed as melanoma showed PRAME expression in more than 50% of the cells. Twelve cases showed expression above 75% of cells and were considered positive for calculations, resulting in sensitivity and specificity rates of 80% and 100%, respectively, with corresponding positive and negative predictive values of 100% and 83%. Conclusions A high level of PRAME immunoreactivity was identified in metastatic melanoma, suggesting that PRAME is a useful analytical tool for confirming the diagnosis of melanoma in a melanocytic nodal deposit.https://doi.org/10.1186/s42047-024-00171-3PRAMEImmunohistochemistryMetastatic melanomaMelanocytic neviSentinel lymph nodes
spellingShingle Hortência Gomes da Silveira
Hercilio Fronza Junior
Larissa D’Espirro de Souza Campos
Jaqueline Stall
Rodrigo Blasius
Camila Kricheski
Bruna Louise Silva
Paulo Henrique Condeixa de França
Karina Munhoz de Paula Alves Coelho
PRAME immunohistochemistry distinguishes nodal nevi from metastatic melanoma
Surgical and Experimental Pathology
PRAME
Immunohistochemistry
Metastatic melanoma
Melanocytic nevi
Sentinel lymph nodes
title PRAME immunohistochemistry distinguishes nodal nevi from metastatic melanoma
title_full PRAME immunohistochemistry distinguishes nodal nevi from metastatic melanoma
title_fullStr PRAME immunohistochemistry distinguishes nodal nevi from metastatic melanoma
title_full_unstemmed PRAME immunohistochemistry distinguishes nodal nevi from metastatic melanoma
title_short PRAME immunohistochemistry distinguishes nodal nevi from metastatic melanoma
title_sort prame immunohistochemistry distinguishes nodal nevi from metastatic melanoma
topic PRAME
Immunohistochemistry
Metastatic melanoma
Melanocytic nevi
Sentinel lymph nodes
url https://doi.org/10.1186/s42047-024-00171-3
work_keys_str_mv AT hortenciagomesdasilveira prameimmunohistochemistrydistinguishesnodalnevifrommetastaticmelanoma
AT herciliofronzajunior prameimmunohistochemistrydistinguishesnodalnevifrommetastaticmelanoma
AT larissadespirrodesouzacampos prameimmunohistochemistrydistinguishesnodalnevifrommetastaticmelanoma
AT jaquelinestall prameimmunohistochemistrydistinguishesnodalnevifrommetastaticmelanoma
AT rodrigoblasius prameimmunohistochemistrydistinguishesnodalnevifrommetastaticmelanoma
AT camilakricheski prameimmunohistochemistrydistinguishesnodalnevifrommetastaticmelanoma
AT brunalouisesilva prameimmunohistochemistrydistinguishesnodalnevifrommetastaticmelanoma
AT paulohenriquecondeixadefranca prameimmunohistochemistrydistinguishesnodalnevifrommetastaticmelanoma
AT karinamunhozdepaulaalvescoelho prameimmunohistochemistrydistinguishesnodalnevifrommetastaticmelanoma